Taking Down Type 2 Inflammatory Disease
Sanofi scientists are working to tame over-active immune responses that drive systemic, chronic diseases
The Fight against COVID-19
As the pandemic continues, Sanofi is at the forefront of vaccine development, while carrying on the daily business of making and delivering medicines for patients
Atopic Dermatitis Across the Ages
Meet three people living with AD as they share how it has affected their lives
DJSI Recognition for Sanofi’s Commitment to Society
Sanofi recognized for its performance for the 14th consecutive year
-
Press releases2020-11-30MMMM DD YYYYDupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis
